Nkarta (NKTX) Stock Forecast & Price Target

Compare

691 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTX Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Nkarta

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTX Stock 12 Month Forecast

Average Price Target

$12.33

▲(559.36% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $12.33 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 559.36% change from the last price of $1.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.11,3.1784615384615384,4.246923076923077,5.315384615384616,6.383846153846154,7.452307692307693,8.52076923076923,9.58923076923077,10.657692307692308,11.726153846153846,12.794615384615385,13.863076923076925,14.931538461538462,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.11,2.896153846153846,3.6823076923076923,4.468461538461538,5.254615384615384,6.0407692307692304,6.826923076923077,7.613076923076923,8.399230769230769,9.185384615384615,9.971538461538461,10.757692307692308,11.543846153846154,{"y":12.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.11,2.7169230769230768,3.323846153846154,3.930769230769231,4.537692307692308,5.144615384615385,5.751538461538463,6.358461538461539,6.965384615384616,7.572307692307692,8.17923076923077,8.786153846153846,9.393076923076924,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$12.33

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Emily Bodnar

H.C. Wainwright

$18→$16

Buy

755.61%

Upside

Reiterated

11/11/25

Nkarta (NKTX) Receives a Buy from H.C. Wainwrightwe have lowered our revenue estimates to account for a later launch. This has resulted in our lower PT of $16 from $18.

Stephen Willey

Stifel Nicolaus

$12→$11

Buy

488.24%

Upside

Reiterated

11/11/25

Nkarta price target lowered to $11 from $12 at StifelNkarta price target lowered to $11 from $12 at Stifel

Gil Blum

Needham

$10

Buy

434.76%

Upside

Reiterated

11/11/25

Nkarta's Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Rallybio (NASDAQ: RLYB) and Nkarta (NASDAQ: NKTX)We remain constructive given the potential for NK cell therapy to show differentiated safety and convenience vs CAR T cells in autoimmune disease (AID), and the substantial unmet need in these diseases. $317M cash supports runway into 2029, ensuring the company is fully funded well past initial POC readouts across several AID indications.

Salim Syed

Mizuho Securities

$14

Buy

648.66%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Daina Graybosch

Leerink Partners

Buy

327.81%

Upside

Reiterated

08/13/25

Leerink Partners Remains a Buy on Nkarta (NKTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sami Corwin

William Blair

―

Hold

―

Reiterated

11/11/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Emily Bodnar

H.C. Wainwright

$18→$16

Buy

755.61%

Upside

Reiterated

11/11/25

Nkarta (NKTX) Receives a Buy from H.C. Wainwrightwe have lowered our revenue estimates to account for a later launch. This has resulted in our lower PT of $16 from $18.

Stephen Willey

Stifel Nicolaus

$12→$11

Buy

488.24%

Upside

Reiterated

11/11/25

Nkarta price target lowered to $11 from $12 at StifelNkarta price target lowered to $11 from $12 at Stifel

Gil Blum

Needham

$10

Buy

434.76%

Upside

Reiterated

11/11/25

Nkarta's Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

11/10/25

Salim Syed

Mizuho Securities

$14

Buy

648.66%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Daina Graybosch

Leerink Partners

Buy

327.81%

Upside

Reiterated

08/13/25

Leerink Partners Remains a Buy on Nkarta (NKTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nkarta

1 Month

xxx

Success Rate

12/26 ratings generated profit

Average Return

+6.07%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +6.07% per trade.

3 Months

xxx

Success Rate

12/30 ratings generated profit

Average Return

+19.33%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +19.33% per trade.

1 Year

Emily BodnarH.C. Wainwright

Success Rate

7/26 ratings generated profit

Average Return

-12.59%

reiterated a buy rating last month

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 26.92% of your transactions generating a profit, with an average return of -12.59% per trade.

2 Years

xxx

Success Rate

3/26 ratings generated profit

Average Return

-38.08%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.54% of your transactions generating a profit, with an average return of -38.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTX has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. NKTX average Analyst price target in the past 3 months is 12.33.

Each month's total comprises the sum of three months' worth of ratings.

NKTX Financial Forecast

NKTX Earnings Forecast

Next quarter’s earnings estimate for NKTX is -$0.31 with a range of -$0.37 to -$0.29. The previous quarter’s EPS was -$0.29. NKTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NKTX has Performed in-line its overall industry.

No data currently available

NKTX Sales Forecast

Next quarter’s sales forecast for NKTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NKTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NKTX has Performed in-line its overall industry.

NKTX Stock Forecast FAQ

What is NKTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nkarta’s 12-month average price target is 12.33.

What is NKTX’s upside potential, based on the analysts’ average price target?

Nkarta has 559.36% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NKTX a Buy, Sell or Hold?

Nkarta has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Nkarta’s price target?

The average price target for Nkarta is 12.33. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $10.00. The average price target represents 559.36% Increase from the current price of $1.87.

What do analysts say about Nkarta?

Nkarta’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of NKTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nkarta (NKTX) Stock Forecast & Price Target

NKTX Analyst Ratings

NKTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nkarta

NKTX Analyst Recommendation Trends

NKTX Financial Forecast

NKTX Earnings Forecast

NKTX Sales Forecast

NKTX Stock Forecast FAQ

Detailed List of Analyst Forecasts